nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonordefrin—ADRA2A—type 2 diabetes mellitus	0.47	1	CbGaD
Levonordefrin—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.126	0.309	CbGbCtD
Levonordefrin—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.119	0.293	CbGbCtD
Levonordefrin—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0829	0.204	CbGbCtD
Levonordefrin—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0795	0.195	CbGbCtD
Levonordefrin—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00437	0.267	CbGeAlD
Levonordefrin—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00294	0.18	CbGeAlD
Levonordefrin—SLC6A2—nerve—type 2 diabetes mellitus	0.00165	0.101	CbGeAlD
Levonordefrin—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.0015	0.0916	CbGeAlD
Levonordefrin—Isoprenaline—PIK3R1—type 2 diabetes mellitus	0.00147	0.243	CrCbGaD
Levonordefrin—Droxidopa—ADRB3—type 2 diabetes mellitus	0.000582	0.0965	CrCbGaD
Levonordefrin—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000571	0.0349	CbGeAlD
Levonordefrin—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000566	0.0346	CbGeAlD
Levonordefrin—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000538	0.0329	CbGeAlD
Levonordefrin—Isoprenaline—ADRB3—type 2 diabetes mellitus	0.000529	0.0877	CrCbGaD
Levonordefrin—ADRA2C—kidney—type 2 diabetes mellitus	0.000502	0.0307	CbGeAlD
Levonordefrin—ADRA2C—pancreas—type 2 diabetes mellitus	0.000499	0.0305	CbGeAlD
Levonordefrin—Norepinephrine—ADRB3—type 2 diabetes mellitus	0.00049	0.0812	CrCbGaD
Levonordefrin—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000489	0.0299	CbGeAlD
Levonordefrin—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000475	0.029	CbGeAlD
Levonordefrin—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000452	0.0277	CbGeAlD
Levonordefrin—Epinephrine—ADRB3—type 2 diabetes mellitus	0.000445	0.0737	CrCbGaD
Levonordefrin—Methyldopa—ADRA2A—type 2 diabetes mellitus	0.000422	0.07	CrCbGaD
Levonordefrin—ADRA2A—pancreas—type 2 diabetes mellitus	0.000398	0.0243	CbGeAlD
Levonordefrin—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.00039	0.0238	CbGeAlD
Levonordefrin—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000361	0.0221	CbGeAlD
Levonordefrin—ADRA1A—liver—type 2 diabetes mellitus	0.000333	0.0204	CbGeAlD
Levonordefrin—ADRA2C—liver—type 2 diabetes mellitus	0.000317	0.0194	CbGeAlD
Levonordefrin—Phenylpropanolamine—ADRA2A—type 2 diabetes mellitus	0.000287	0.0476	CrCbGaD
Levonordefrin—Droxidopa—ADRA2A—type 2 diabetes mellitus	0.000264	0.0437	CrCbGaD
Levonordefrin—Norepinephrine—ADRA2A—type 2 diabetes mellitus	0.000222	0.0368	CrCbGaD
Levonordefrin—Salbutamol—CYP3A4—type 2 diabetes mellitus	0.000205	0.034	CrCbGaD
Levonordefrin—Epinephrine—ADRA2A—type 2 diabetes mellitus	0.000201	0.0334	CrCbGaD
Levonordefrin—Phenylpropanolamine—CYP1A2—type 2 diabetes mellitus	0.000199	0.0331	CrCbGaD
Levonordefrin—Epinephrine—TNF—type 2 diabetes mellitus	0.000191	0.0316	CrCbGaD
Levonordefrin—Norepinephrine—CYP1A2—type 2 diabetes mellitus	0.000154	0.0255	CrCbGaD
Levonordefrin—Dopamine—CYP1A2—type 2 diabetes mellitus	0.000143	0.0237	CrCbGaD
Levonordefrin—Epinephrine—CYP1A2—type 2 diabetes mellitus	0.00014	0.0232	CrCbGaD
Levonordefrin—Epinephrine—CYP3A4—type 2 diabetes mellitus	9.26e-05	0.0153	CrCbGaD
Levonordefrin—ADRA1A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.26e-05	0.000126	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—GPX1—type 2 diabetes mellitus	1.26e-05	0.000126	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.25e-05	0.000125	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.25e-05	0.000125	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.25e-05	0.000125	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.25e-05	0.000125	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.24e-05	0.000125	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.24e-05	0.000124	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.24e-05	0.000124	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.23e-05	0.000123	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—CD36—type 2 diabetes mellitus	1.22e-05	0.000122	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.22e-05	0.000122	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.22e-05	0.000122	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.22e-05	0.000122	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.21e-05	0.000122	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—PPP2CA—type 2 diabetes mellitus	1.21e-05	0.000121	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—APOB—type 2 diabetes mellitus	1.21e-05	0.000121	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.2e-05	0.000121	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.2e-05	0.00012	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.2e-05	0.00012	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.2e-05	0.00012	CbGpPWpGaD
Levonordefrin—ADRA2A—Hemostasis—SRC—type 2 diabetes mellitus	1.2e-05	0.00012	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.19e-05	0.00012	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.19e-05	0.000119	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.18e-05	0.000118	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.18e-05	0.000118	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.18e-05	0.000118	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.17e-05	0.000117	CbGpPWpGaD
Levonordefrin—ADRA2A—Hemostasis—VEGFA—type 2 diabetes mellitus	1.17e-05	0.000117	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—AVP—type 2 diabetes mellitus	1.17e-05	0.000117	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.17e-05	0.000117	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.16e-05	0.000116	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—MTHFR—type 2 diabetes mellitus	1.16e-05	0.000116	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.16e-05	0.000116	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—LPL—type 2 diabetes mellitus	1.15e-05	0.000115	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—GNB3—type 2 diabetes mellitus	1.15e-05	0.000115	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.15e-05	0.000115	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.14e-05	0.000115	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—HMOX1—type 2 diabetes mellitus	1.14e-05	0.000114	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—PPARA—type 2 diabetes mellitus	1.14e-05	0.000114	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.13e-05	0.000113	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.13e-05	0.000113	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.13e-05	0.000113	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—CAT—type 2 diabetes mellitus	1.13e-05	0.000113	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—APOB—type 2 diabetes mellitus	1.13e-05	0.000113	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.12e-05	0.000112	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.12e-05	0.000112	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.11e-05	0.000112	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.11e-05	0.000112	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.11e-05	0.000111	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.1e-05	0.00011	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.1e-05	0.00011	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—AGT—type 2 diabetes mellitus	1.1e-05	0.00011	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.1e-05	0.00011	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—APOB—type 2 diabetes mellitus	1.1e-05	0.00011	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.09e-05	0.000109	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—CALM1—type 2 diabetes mellitus	1.08e-05	0.000108	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.08e-05	0.000108	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—APOE—type 2 diabetes mellitus	1.08e-05	0.000108	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—LPL—type 2 diabetes mellitus	1.08e-05	0.000108	CbGpPWpGaD
Levonordefrin—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	1.07e-05	0.000107	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	1.07e-05	0.000107	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	1.07e-05	0.000107	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.06e-05	0.000106	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.05e-05	0.000106	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	1.05e-05	0.000105	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.04e-05	0.000104	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.04e-05	0.000104	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	1.04e-05	0.000104	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.03e-05	0.000104	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.02e-05	0.000103	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	1.02e-05	0.000103	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.02e-05	0.000102	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	1.02e-05	0.000102	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.02e-05	0.000102	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	1.02e-05	0.000102	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.02e-05	0.000102	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.01e-05	0.000101	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.01e-05	0.000101	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1e-05	0.0001	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	9.94e-06	9.95e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.92e-06	9.93e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.9e-06	9.91e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.87e-06	9.88e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	9.86e-06	9.87e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	9.86e-06	9.87e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.82e-06	9.83e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	9.81e-06	9.83e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	9.81e-06	9.82e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.7e-06	9.71e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.7e-06	9.71e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.7e-06	9.71e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	9.69e-06	9.71e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	9.66e-06	9.67e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	9.66e-06	9.67e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.61e-06	9.62e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.55e-06	9.56e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	9.48e-06	9.49e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.48e-06	9.49e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.43e-06	9.45e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	9.42e-06	9.43e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	9.41e-06	9.42e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	9.4e-06	9.41e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.39e-06	9.4e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.3e-06	9.31e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.25e-06	9.26e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	9.24e-06	9.25e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.22e-06	9.23e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	9.22e-06	9.23e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.21e-06	9.23e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	9.21e-06	9.22e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	9.17e-06	9.18e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	9.16e-06	9.17e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.12e-06	9.13e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	9.11e-06	9.12e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.06e-06	9.07e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	9.03e-06	9.04e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	9.03e-06	9.04e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.01e-06	9.02e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	8.95e-06	8.96e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.92e-06	8.93e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.83e-06	8.84e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	8.8e-06	8.81e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	8.77e-06	8.78e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.75e-06	8.76e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.67e-06	8.68e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	8.67e-06	8.68e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.62e-06	8.63e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.56e-06	8.57e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.51e-06	8.52e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	8.47e-06	8.48e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	8.45e-06	8.46e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	8.25e-06	8.26e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.21e-06	8.22e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	8.12e-06	8.13e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	8.09e-06	8.1e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	8.09e-06	8.1e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.08e-06	8.09e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.06e-06	8.07e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.06e-06	8.07e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	8.05e-06	8.06e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.05e-06	8.06e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.98e-06	7.99e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.98e-06	7.99e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.94e-06	7.95e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.92e-06	7.93e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.89e-06	7.9e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.89e-06	7.9e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	7.87e-06	7.88e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.8e-06	7.81e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	7.71e-06	7.72e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	7.64e-06	7.65e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.59e-06	7.59e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.58e-06	7.59e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.51e-06	7.52e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.49e-06	7.5e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	7.49e-06	7.5e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	7.48e-06	7.49e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.46e-06	7.47e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.45e-06	7.46e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	7.45e-06	7.46e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.44e-06	7.45e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.42e-06	7.43e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	7.4e-06	7.4e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.36e-06	7.37e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.33e-06	7.34e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.33e-06	7.34e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.25e-06	7.26e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.24e-06	7.25e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.24e-06	7.25e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.08e-06	7.09e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.04e-06	7.05e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.91e-06	6.92e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	6.87e-06	6.87e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	6.81e-06	6.82e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.76e-06	6.77e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.76e-06	6.77e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	6.74e-06	6.75e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.63e-06	6.64e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	6.57e-06	6.58e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	6.57e-06	6.58e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.54e-06	6.55e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.52e-06	6.53e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.51e-06	6.52e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.49e-06	6.49e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	6.36e-06	6.37e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	6.26e-06	6.27e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.2e-06	6.21e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.19e-06	6.2e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.16e-06	6.17e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.15e-06	6.15e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.11e-06	6.11e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.06e-06	6.06e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.05e-06	6.06e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.03e-06	6.03e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	6.01e-06	6.01e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.91e-06	5.92e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.91e-06	5.92e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.81e-06	5.81e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.79e-06	5.8e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.75e-06	5.76e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.75e-06	5.75e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.74e-06	5.75e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.7e-06	5.71e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.63e-06	5.64e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.56e-06	5.57e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.49e-06	5.5e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.49e-06	5.5e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.42e-06	5.43e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.37e-06	5.37e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	5.35e-06	5.36e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.26e-06	5.27e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.21e-06	5.22e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.17e-06	5.18e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.06e-06	5.07e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.02e-06	5.02e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	5e-06	5.01e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.99e-06	4.99e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.87e-06	4.88e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.79e-06	4.79e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.74e-06	4.75e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.71e-06	4.71e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.69e-06	4.7e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.69e-06	4.7e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.66e-06	4.67e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.63e-06	4.64e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.6e-06	4.6e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.47e-06	4.48e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.41e-06	4.41e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.38e-06	4.39e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.37e-06	4.38e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.36e-06	4.36e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.27e-06	4.28e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.26e-06	4.26e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.06e-06	4.07e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.96e-06	3.96e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.91e-06	3.91e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.83e-06	3.84e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	3.72e-06	3.72e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.63e-06	3.64e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.61e-06	3.61e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.56e-06	3.56e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	3.37e-06	3.37e-05	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.33e-06	3.33e-05	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.11e-06	3.11e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	3.02e-06	3.02e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.95e-06	2.95e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.74e-06	2.74e-05	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.72e-06	2.72e-05	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.52e-06	2.53e-05	CbGpPWpGaD
